Article Details

Urogen Pharma (NASDAQ:URGN) Receives Buy Rating from Cowen

Retrieved on: 2018-08-31 14:00:00

Tags for this article:

Click the tags to see associated articles and topics

Urogen Pharma (NASDAQ:URGN) Receives Buy Rating from Cowen. View article details on hiswai:

Excerpt

<div><b>Two Sigma Investments</b> LP acquired a new position in Urogen Pharma in the fourth quarter valued at $277,000. Millennium Management LLC ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo